Patents by Inventor Ellen Filvaroff

Ellen Filvaroff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11460471
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: October 4, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
  • Publication number: 20220298222
    Abstract: Provided are methods, uses, and articles of manufacture of combination therapies involving immunotherapies and cell therapies, such as adoptive cell therapy, e.g. a T cell therapy, and the use of an inhibitor of an enhancer of zeste homolog 2 (EZH2), for treating subjects having or suspected of having a cancer, and related methods, uses, and articles of manufacture. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs).
    Type: Application
    Filed: August 21, 2020
    Publication date: September 22, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Henry CHANG, Ellen FILVAROFF, Brian FOX, Adithi MOHAN, Katie NEWHALL, Nels Eric OLSON
  • Publication number: 20220273654
    Abstract: Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 1, 2022
    Applicant: Celgene Corporation
    Inventors: Ellen Filvaroff, Brian Fox, Ida Aronchik, Tracy Chow
  • Publication number: 20220265618
    Abstract: The present application relates generally to methods for treating prostate cancer with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2- methylisoquinolin-1-one as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Applicant: Celgene Quanticel Research, Inc.
    Inventors: Martina Malatesta, Ellen Filvaroff
  • Publication number: 20220175770
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Application
    Filed: July 20, 2021
    Publication date: June 9, 2022
    Inventors: Ellen FILVAROFF, Kristen M. HEGE, Shaoyi LI
  • Patent number: 11096940
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: August 24, 2021
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Kristen M. Hege, Shaoyi Li
  • Publication number: 20210254000
    Abstract: Provided herein are methods for producing engineered T cells that express a recombinant receptor, such as for use in cell therapy. In some aspects, the provided methods include one or more steps for incubating the cells under stimulating conditions, introducing a recombinant polypeptide to the cells through transduction or transfection, and/or cultivating the cells under conditions that promote proliferation and/or expansion, in which one or more steps is carried out in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, cultivation is performed in the presence of an agent that inhibits mammalian target of rapamycin (mTOR) activity. In some aspects, the provided methods produce genetically engineered T cells with improved persistence and/or anti-tumor activity in vivo.
    Type: Application
    Filed: November 1, 2018
    Publication date: August 19, 2021
    Applicants: Juno Therapeutics, Inc., Celgene Corporation
    Inventors: Archana BRAHMANDAM, Lucas James THOMPSON, Deborah MORTENSEN, Ellen FILVAROFF
  • Publication number: 20210113576
    Abstract: Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing hematological malignancies. The second active agent is one or more of an HDAC inhibitor, a BCL2 inhibitor, a BTK inhibitor, an mTOR inhibitor, a PI3K inhibitor, a PKC? inhibitor, a SYK inhibitor, a JAK2 inhibitor, an Aurora kinase inhibitor, an EZH2 inhibitor, a BET inhibitor, a hypomethylating agent, a DOT1L inhibitor, a HAT inhibitor, a WDR5 inhibitor, a DNMT1 inhibitor, an LSD-1 inhibitor, a G9A inhibitor, a PRMT5 inhibitor, a BRD inhibitor, a SUV420H1/H2 inhibitor, a CARM1 inhibitor, a PLK1 inhibitor, an NEK2 inhibitor, an MEK inhibitor, a PHF19 inhibitor, a PIM inhibitor, an IGF-1R inhibitor, an XPO1 inhibitor, a BIRC5 inhibitor, or a chemotherapy.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 22, 2021
    Inventors: Maria Soraya Carrancio Anton, Tonia J. Buchholz, Henry Chang, Ellen Filvaroff, Shailaja Kasibhatla, Antonia Lopez-Girona, Adithi Mohan, Rama Krishna Narla, Michael Pourdehnad
  • Publication number: 20200333340
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Application
    Filed: April 3, 2020
    Publication date: October 22, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Ellen FILVAROFF, Antonia LOPEZ-GIRONA, Gang LU
  • Patent number: 10648983
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 12, 2020
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
  • Publication number: 20200121676
    Abstract: Provided herein are methods for treating and/or preventing hepatocellular carcinoma (HCC) characterized by hepatitis B virus (HBV) infection in a patient, comprising administering an effective amount of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt or tautomer thereof (collectively referred to herein as “Compound 1”) to the patient having HCC characterized by HBV infection.
    Type: Application
    Filed: June 21, 2018
    Publication date: April 23, 2020
    Inventors: Ellen FILVAROFF, Kristen M. HEGE, Shaoyi LI
  • Patent number: 10576085
    Abstract: Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 3, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: John F. Boylan, Gordon L. Bray, Ellen Filvaroff, Robert Hubbard, David Mikolon, Heather Raymon, Tao Shi, Tam M. Tran, Toshiya Tsuji, Lilly L. Wong, Shuichan Xu, Dan Zhu
  • Publication number: 20200046696
    Abstract: Provided herein are methods of treating NMD-dependent tumors by administering an SMG1-inhibitor to a patient in need of such treatment and combination therapies comprising the same.
    Type: Application
    Filed: February 13, 2018
    Publication date: February 13, 2020
    Inventor: Ellen Filvaroff
  • Publication number: 20180369241
    Abstract: Provided herein are methods for treating or preventing Wnt-associated cancers, comprising administering an effective amount of a DNAPK inhibitor to a patient having a Wnt-associated cancer.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 27, 2018
    Inventors: Felix Yi-Chung FENG, Ellen FILVAROFF, Kristen Mae HEGE, Vishal KOTHARI, Shuang ZHAO
  • Publication number: 20170281633
    Abstract: Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 5, 2017
    Inventors: John F. Boylan, Gordon L. Bray, Ellen Filvaroff, Robert Hubbard, David Mikolon, Heather Raymon, Tao Shi, Tam M. Tran, Toshiya Tsuji, Lilly L. Wong, Shuichan Xu, Dan Zhu
  • Publication number: 20170199193
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Application
    Filed: January 6, 2017
    Publication date: July 13, 2017
    Inventors: Ellen FILVAROFF, Antonia LOPEZ-GIRONA, Gang LU
  • Publication number: 20160303127
    Abstract: The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer.
    Type: Application
    Filed: December 17, 2015
    Publication date: October 20, 2016
    Inventors: Ellen FILVAROFF, Mark MERCHANT, Robert L. YAUCH
  • Publication number: 20150266953
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: December 23, 2014
    Publication date: September 24, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jian CHEN, Ellen FILVAROFF, Sherman FONG, Dorothy FRENCH, Audrey GODDARD, Paul J. GODOWSKI, J. Christopher GRIMALDI, Austin L. GUMEY, Kenneth J. HILLAN, Sarah G. HYMOWITZ, Hanzhong LI, James Pan ZTUBICOKE, Melissa A. STAROVASNIK, Daniel TUMAS, Menno VAN LOOKEREN, Richard VANDLEN, Colin K. WATANABE, P. Mickey WILLIAMS, William I. WOOD, Daniel G. YANSURA
  • Publication number: 20150141283
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: September 17, 2014
    Publication date: May 21, 2015
    Applicant: GENENTECH, INC.
    Inventors: Jian CHEN, Ellen FILVAROFF, Sherman FONG, Dorothy FRENCH, Audrey GODDARD, Paul J. GODOWSKI, J. Christopher GRIMALDI, Austin L. GURNEY, Kenneth J. HILIAN, Sarah G. HYMOWITZ, Hanzhong LI, Melissa A. STAROVASNIK, Daniel TUMAS, Menno VAN LOOKEREN, Richard VANDLEN, Colin K. WATANABE, P. Mickey WILLIAMS, William I. WOOD, Daniel G. YANSURA, James PAN
  • Publication number: 20150099754
    Abstract: Provided herein are methods for treating and/or preventing a cancer in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer characterized by particular gene mutation(s) or variant(s) relative to the genes of a biological wild-type sample.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Shuichan Xu, Kristen Mae Hege, Xiaoling Wu, Zhihong Yang, Konstantinos Mavrommatis, Ellen Filvaroff